Study suggests similarity between biosimilar GBR 310 and omalizumab: Glenmark

Glenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news